238 related articles for article (PubMed ID: 36211384)
1. Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension.
Didriksen H; Molberg Ø; Mehta A; Jordan S; Palchevskiy V; Fretheim H; Gude E; Ueland T; Brunborg C; Garen T; Midtvedt Ø; Andreassen AK; Lund-Johansen F; Distler O; Belperio J; Hoffmann-Vold AM
Front Immunol; 2022; 13():991743. PubMed ID: 36211384
[TBL] [Abstract][Full Text] [Related]
2. CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis.
Hoffmann-Vold AM; Hesselstrand R; Fretheim H; Ueland T; Andreassen AK; Brunborg C; Palchevskiy V; Midtvedt Ø; Garen T; Aukrust P; Belperio JA; Molberg Ø
Arthritis Rheumatol; 2018 Oct; 70(10):1644-1653. PubMed ID: 29687634
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension.
Di Benedetto P; Guggino G; Manzi G; Ruscitti P; Berardicurti O; Panzera N; Grazia N; Badagliacca R; Riccieri V; Vizza CD; Radchenko G; Liakouli V; Ciccia F; Cipriani P; Giacomelli R
Arthritis Res Ther; 2020 Jun; 22(1):127. PubMed ID: 32487240
[TBL] [Abstract][Full Text] [Related]
4. Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension.
Sanges S; Guerrier T; Duhamel A; Guilbert L; Hauspie C; Largy A; Balden M; Podevin C; Lefèvre G; Jendoubi M; Speca S; Hachulla É; Sobanski V; Dubucquoi S; Launay D
Front Immunol; 2022; 13():954007. PubMed ID: 35967377
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis.
Sanges S; Rice L; Tu L; Valenzi E; Cracowski JL; Montani D; Mantero JC; Ternynck C; Marot G; Bujor AM; Hachulla E; Launay D; Humbert M; Guignabert C; Lafyatis R
Ann Rheum Dis; 2023 Mar; 82(3):365-373. PubMed ID: 36600187
[TBL] [Abstract][Full Text] [Related]
6. Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis.
Didriksen H; Molberg Ø; Fretheim H; Gude E; Jordan S; Brunborg C; Palchevskiy V; Garen T; Midtvedt Ø; Andreassen AK; Distler O; Belperio J; Hoffmann-Vold AM
Arthritis Rheumatol; 2021 Jul; 73(7):1277-1287. PubMed ID: 33497027
[TBL] [Abstract][Full Text] [Related]
7. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
[TBL] [Abstract][Full Text] [Related]
8. Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis.
Rice LM; Mantero JC; Stratton EA; Warburton R; Roberts K; Hill N; Simms RW; Domsic R; Farber HW; Layfatis R
Arthritis Res Ther; 2018 Aug; 20(1):185. PubMed ID: 30115106
[TBL] [Abstract][Full Text] [Related]
9. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G
Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620
[TBL] [Abstract][Full Text] [Related]
10. Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension.
Corrado A; Correale M; Mansueto N; Monaco I; Carriero A; Mele A; Colia R; Di Biase M; Cantatore FP
Microvasc Res; 2017 Nov; 114():46-51. PubMed ID: 28619664
[TBL] [Abstract][Full Text] [Related]
11. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis.
Atzeni IM; Al-Adwi Y; Doornbos-van der Meer B; Roozendaal C; Stel A; van Goor H; Gan CT; Dickinson M; Timens W; Smit AJ; Westra J; Mulder DJ
Front Immunol; 2023; 14():1189257. PubMed ID: 37409127
[TBL] [Abstract][Full Text] [Related]
12. Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study.
Vadasz Z; Balbir Gurman A; Meroni P; Farge D; Levi Y; Ingegnoli F; Braun-Moscovici Y; Rosner I; Slobodin G; Rozenbaum M; Jiries N; Kaly L; Boulman N; Zilber K; Ginsberg S; Awisat A; Goldberg Y; Lurie M; Ghigna MR; Guignabert C; Humbert M; Rimar D
Rheumatology (Oxford); 2019 Sep; 58(9):1547-1555. PubMed ID: 30770717
[TBL] [Abstract][Full Text] [Related]
13. Scleroderma pulmonary arterial hypertension: the same as idiopathic pulmonary arterial hypertension?
Khan SL; Mathai SC
Curr Opin Pulm Med; 2023 Sep; 29(5):380-390. PubMed ID: 37461869
[TBL] [Abstract][Full Text] [Related]
14. Altered Cellular Immunity and Differentially Expressed Immune-Related Genes in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
Tu J; Jin J; Chen X; Sun L; Cai Z
Front Immunol; 2022; 13():868983. PubMed ID: 35663995
[TBL] [Abstract][Full Text] [Related]
15. Protein profiling in systemic sclerosis patients with different pulmonary complications using proteomic antibody microarray.
Huang J; Zhu H; Liu S; Li M; Li Y; Luo H; Zuo X
Arthritis Res Ther; 2024 Jan; 26(1):29. PubMed ID: 38233947
[TBL] [Abstract][Full Text] [Related]
16. Kynurenine pathway metabolism evolves with development of preclinical and scleroderma-associated pulmonary arterial hypertension.
Simpson CE; Ambade AS; Harlan R; Roux A; Aja S; Graham D; Shah AA; Hummers LK; Hemnes AR; Leopold JA; Horn EM; Berman-Rosenzweig ES; Grunig G; Aldred MA; Barnard J; Comhair SAA; Tang WHW; Griffiths M; Rischard F; Frantz RP; Erzurum SC; Beck GJ; Hill NS; Mathai SC; Hassoun PM; Damico RL;
Am J Physiol Lung Cell Mol Physiol; 2023 Nov; 325(5):L617-L627. PubMed ID: 37786941
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension.
Meadows CA; Risbano MG; Zhang L; Geraci MW; Tuder RM; Collier DH; Bull TM
Chest; 2011 May; 139(5):994-1002. PubMed ID: 20829333
[TBL] [Abstract][Full Text] [Related]
18. Insufficient Evidence to Consider CCL21 a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann-Vold et al.
Xu WD; Su LC; Huang AF
Arthritis Rheumatol; 2019 Apr; 71(4):654-655. PubMed ID: 30653848
[No Abstract] [Full Text] [Related]
19. Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis.
Ikawa T; Miyagawa T; Fukui Y; Minatsuki S; Maki H; Inaba T; Hatano M; Toyama S; Omatsu J; Awaji K; Norimatsu Y; Watanabe Y; Yoshizaki A; Sato S; Asano Y
Int J Rheum Dis; 2021 May; 24(5):711-718. PubMed ID: 33750014
[TBL] [Abstract][Full Text] [Related]
20. Aberrant long-chain fatty acid metabolism associated with evolving systemic sclerosis-associated pulmonary arterial hypertension.
Coursen JC; Tuhy T; Naranjo M; Woods A; Hummers LK; Shah AA; Suresh K; Visovatti SH; Mathai SC; Hassoun PM; Damico RL; Simpson CE
Am J Physiol Lung Cell Mol Physiol; 2024 Jul; 327(1):L54-L64. PubMed ID: 38651694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
